Project Grant HT94252510023
Award Date
6/1/25
Completion Date
5/31/28
Dollars Obligated
$801K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
This $871,016 Project Grant awarded on January 1, 2024 by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Beckman Research Institute of the City of Hope supports research on a highly tumor-specific oncolytic virus combined with a viral protein-target T cell engager for the treatment of triple-negative breast cancer. The grant aims to develop innovative therapies for this aggressive form of breast cancer that impacts military personnel and veterans. As a...
The Department of Defense's Defense Health Agency awarded a $447,612 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Beckman Research Institute of the City of Hope. The grant supports the development of a "highly tumor-specific oncolytic virus in combination with a viral protein-target T cell engager for the treatment of triple-negative breast cancer." The award period runs from January 1, 2024 to December 31, 2026. As a nonprofit...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This federal Project Grant award, valued at $1,301,250.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports a research project titled "INHIBITING MDSC BIOGENESIS TO AUGMENT IMMUNOTHERAPY EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER" at Health Research, Inc.'s Roswell Park Division. The research aims to investigate innovative approaches to enhancing the efficacy of immunotherapy for triple-negative...
The federal Project Grant award, totaling $505,071.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by The University of Texas MD Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The research initiative aims to transform healthcare for military service members and the general public through innovative and impactful cancer...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
The Defense Health Agency awarded a $579,375 Project Grant to the University of Nebraska Medical Center through the Military Medical Research and Development program (CFDA 12.420) to support research targeting APE1 interaction with DNA G-quadruplex to prevent metastasis in triple-negative breast cancer. The three-year award beginning December 30, 2022 will fund research by the University of Nebraska Medical Center to investigate medical solutions for metastatic breast cancer through innovative...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...